Streetbeat News

ANVS

Annovis Bio, Inc.

https://www.annovisbio.com

Industry

Biotechnology

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

NIO Inc. (NYSE:NIO) shares fell 8.5% after the resignation of CFO Steven Wei Feng. Other notable movers include Qualigen Therapeutics, Inc. (NASDAQ:QLGN) up 120%, Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) up 70.5%, and Macy’s, Inc. (NYSE:M) up 10.4% due to an increased acquisition bid. XPeng Inc. (NYSE:XPEV) declined 10% after announcing vehicle delivery figures.

Portfolio Pulse from Avi Kapoor

July 05, 2024 | 4:59 pm

Annovis Bio (NYSE:ANVS) has seen a 5.24% increase in its short percent of float, now at 15.27%. This is higher than its peers' average of 8.26%. The company has 1.28 million shares sold short, taking traders an average of 5.96 days to cover their positions.

Portfolio Pulse from Benzinga Insights

July 05, 2024 | 2:59 pm

Annovis Bio, Inc. (NYSE:ANVS) shares are gaining in premarket trading following a 76% increase in the previous session. The company announced positive data from its Phase III Parkinson’s study, showing improvements in the Unified Parkinson’s Disease Rating Scale with its treatment, buntanetap. Additionally, Annovis filed a provisional patent for the manufacturing process of new solid forms of buntanetap.

Portfolio Pulse from Nabaparna Bhattacharya

July 03, 2024 | 11:12 am

On Tuesday, the Dow Jones, S&P 500, and Nasdaq all closed higher. Tesla, Paramount Global, Annovis Bio, Eli Lilly, and Amazon were notable stocks. Tesla surged on strong deliveries, Paramount rose on takeover speculation, Annovis Bio soared on positive drug trial data, Eli Lilly fell due to political pressure on drug prices, and Amazon hit new highs on AI optimism.

Portfolio Pulse from Benzinga Neuro

July 03, 2024 | 3:38 am

Annovis Bio shares were halted on a circuit breaker due to a significant upward movement, with the stock now up by 101.5%.